A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma.

@article{Hwang2011AMP,
  title={A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma.},
  author={Tae-ho Hwang and Anne Moon and James P. Burke and Antoni Ribas and Joe Stephenson and Caroline J. Breitbach and Manijeh Daneshmand and Naomi De Silva and Kelley A. Parato and Jean-Simon Diallo and Yeon-Sook Lee and T Liu and John Cameron Bell and David H. Kirn},
  journal={Molecular therapy : the journal of the American Society of Gene Therapy},
  year={2011},
  volume={19 10},
  pages={1913-22}
}
JX-594 is a targeted and granulocyte macrophage-colony stimulating factor (GM-CSF)-expressing oncolytic poxvirus designed to selectively replicate in and destroy cancer cells through viral oncolysis and tumor-specific immunity. In order to study the mechanisms-of-action (MOA) of JX-594 in humans, a mechanistic proof-of-concept clinical trial was performed at a low dose equivalent to ≤10% of the maximum-tolerated dose (MTD) in other clinical trials. Ten patients with previously treated stage IV… CONTINUE READING